Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative radiotherapy before radical cystectomy combined with nivolumab in locally advanced urothelial bladder cancer
2018-001823-38Phase 2Completed
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: Rate of completed treatment by end of week 15. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on 2018-001823-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001823-38.